25 results about "Aldosterone" patented technology

The invention relates to the technical field of medical detection, in particular to a method for detecting aldosterone, cortisol, deoxycorticosterone and cortisone in plasma through LC-MS / MS. The method comprises the following steps: (a) mixing a plasma sample with an internal standard solution to obtain a mixed solution; (b) adding the mixed solution into the magnetic bead suspension, sequentially carrying out adsorption, weak washing, strong washing and elution, and collecting an eluent; (c) carrying out liquid nitrogen blowing and redissolving on the eluent, and then carrying out LC-MS / MS detection; wherein the surfaces of the magnetic beads are modified with steroid adsorption groups, and the target detection objects are aldosterone, cortisol, deoxycorticosterone and cortisone. The detection method is convenient and simple, the detection efficiency is higher than that of a traditional method, and a feasible solution is provided for promoting popularization and application of the LC-MS / MS technology in clinical practice.

The present invention relates to novel compounds and pharmaceutical compositions thereof, and to methods for promoting healthy skin aging, treating skin disorders, treating cardiovascular disorders, treating renal disorders, treating angiogenesis disorders, such as cancer, treating tissue damage, such as non-cardiac tissue damage, treating progressive myocardial infarction, and treating various other disorders, such as complications resulting from diabetes with the compounds and compositions of the invention. Other disorders may include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, skin infections, peripheral vascular disease, stroke, and the like.

This application belongs to the field of immunoassay technology, and discloses an aldosterone sandwich antibody mAb5 or its antigen-binding fragment, its preparation method, and its applications. The aldosterone sandwich antibody mAb5 or its antigen-binding fragment includes a light chain variable region (VL) and a heavy chain variable region (VH). The light chain variable region (VL) includes complementarity-determining regions (LCDR1, LCDR2, and LCDR3), whose amino acid sequences are shown in SEQ ID NO. 1-3, respectively. The heavy chain variable region (VH) includes complementarity-determining regions (HCDR1, HCDR2, and HCDR3), whose amino acid sequences are shown in SEQ ID NO. 4-6, respectively. Using the aldosterone sandwich antibody mAb5 of this application to detect aldosterone standard antigens, the detection sensitivity is less than 7 pg / mL. Magnetochemiluminescence immunoassay of clinical samples shows good correlation with clinical results within the sample range of 0-1000 pg / mL, which is of great significance in the diagnosis and treatment of essential hypertension and other aldosterone-related diseases.

The application discloses a plant extraction compound for reducing blood pressure, a preparation method and application thereof. The compound is composed of high-purity silybin extract and a specific fusion polypeptide through molecular self-assembly. The sequence of the fusion polypeptide is shown in sequence SEQ ID NO:1, which innovatively integrates cell membrane penetration function, angiotensin II receptor 1 antagonism function and hydrophobic drug binding function. The core of the application is that through polypeptide-mediated active targeting, silybin is accurately delivered to the diseased blood vessel area, and the double synergistic mechanism of upstream ACE inhibition and downstream receptor blocking of the renin-angiotensin-aldosterone system is realized. In-vivo pharmacodynamic experiments prove that compared with single components, the compound can produce more significant and persistent antihypertensive effect, and can effectively reverse myocardial hypertrophy and fibrosis caused by hypertension, and show excellent synergistic therapeutic effect and target organ protection ability.

Embodiments provide for methods of treatment for subjects suffering from a condition / disorder or disease for which the renin-angiotensin-aldosterone system (RAAS) plays at least some role. In one example, a method comprises administering to the subject an effective amount of one or more of an angiotensin receptor AT2R antagonist for a duration sufficient to elicit a desired response in the subject suffering from pancreatic cancer. The administering acts to reduce proliferation of tumor cells associated with the pancreatic cancer.

The application discloses a nucleic acid aptamer and derivatives, application and kit capable of specifically combining with aldosterone, and comprises a nucleotide sequence shown in SEQ ID No. 1, or a nucleotide sequence with high homology with the nucleotide sequence shown in SEQ ID No. 1 and capable of specifically combining with aldosterone, or a nucleotide sequence derived from the nucleotide sequence shown in SEQ ID No. 1 and capable of specifically combining with aldosterone. The application provides a nucleic acid aptamer and derivatives capable of combining with aldosterone, which have high specificity, stable chemical properties, are easy to preserve and label, and also correspondingly provides a screening method and application of the nucleic acid aptamer.

The invention relates to the technical field of molecular biology, and provides a marker combination for diagnosing neonatal necrotizing enterocolitis and application thereof. The marker combination comprises a CC chemokine ligand 20, a heparin binding epidermal growth factor, angiotensin and aldosterone. Four markers related to neonatal necrotizing enterocolitis are obtained through research and screening, whether neonatal necrotizing enterocolitis occurs or not and the severity of neonatal necrotizing enterocolitis can be effectively judged based on the markers, and the markers have high sensitivity and specificity and can be used for detecting neonatal necrotizing enterocolitis. The kit can help clinical diagnosis and prognosis of neonatal necrotizing enterocolitis.

The invention discloses an anti-aldosterone antibody and application thereof, and relates to the field of antibodies. The anti-aldosterone antibody disclosed by the invention comprises a heavy chain complementarity determining region and a light chain complementarity determining region, provides an important raw material source for aldosterone detection, and has good affinity or activity.

The present invention belongs to the technical field of chemical pharmaceuticals. Provided in the present invention are an aldosterone synthetase inhibitor, and a preparation method therefor and the use thereof.

The invention discloses a protein pretreatment method, a renin angiotensin aldosterone system index detection method, a kit and application, and relates to the field of liquid chromatography-tandem mass spectrometry detection.The protein pretreatment method comprises the following steps that a biological sample containing renin angiotensin aldosterone system indexes is taken; mixing with an inhibitor solution, incubating, and adding a terminating agent to terminate the reaction to obtain an incubation solution; uniformly mixing the incubation solution with an internal standard solution and a protein precipitant, sequentially standing, centrifuging, and collecting supernate to obtain a sample to be detected. The protein precipitation pretreatment method provided by the invention can simplify the operation process, reduce the experiment cost, adapt to large-scale detection, efficiently remove impure proteins, weaken the matrix effect and improve the detection sensitivity and accuracy of a target object, and has a wide application prospect in the related field of RAAS system index detection.

The aim is to provide plasma biomarkers for bone infections in humans. [Solution] A plasma biomarker for bone infection comprising one or more substances selected from the group consisting of sphingosine-1-phosphate, taurocholic acid, glycololic acid, 11a,b hydroxyprogesterone, 15(S)-HETE-2, 13-dehydrochenodeoxycholic acid, 3,21-didihydroxy-5a-pregnane-20-one-2, aldosterone, bisacron-2, naringenin, tauro-α-mulicolic acid-6, 1-deoxysphingosine, 12(S)-HETE-2, 2-arachidonoylglycerol, 3-hydroxydodecanoic acid, 3-hydroxytetradecanoic acid, 3b-hydroxy-5-cholestic acid, AEA(22:4)-1, AEA(22:4)-2, bilbertin, sphingosine, malic acid, and succinic acid.

The invention discloses an essential oil pellet for resisting stress of cats as well as a preparation method and application of the essential oil pellet, and belongs to the technical field of veterinary traditional Chinese medicine preparations. The essential oil pellet is prepared from the following raw materials: extracts of wormwood, lavender and rhizoma acori graminei; the mass ratio of wormwood to lavender to rhizoma acori graminei is (1-2): (1-2): (1-2). The essential oil pellet prepared by the invention is filled into a nylon bag to prepare a sachet, and the sachet is suspended on the neck of a cat, added into a cat collar or put into cat clothes for use, so that the anti-stress capability of the cat can be remarkably improved, specifically, the feed intake of the cat is improved, and the weight of the cat is increased; meanwhile, the antioxidant index is improved, and the level of oxidative metabolite MDA in blood is reduced; in addition, the levels of cortisol and aldosterone as stress hormones and interleukin-6 as an inflammatory cytokine in cat serum can also be reduced.

The invention belongs to the technical field of chemical drugs and provides an aldosterone synthetase inhibitor as well as a preparation method and application thereof.

The invention belongs to the technical field of immunodetection, and discloses an aldosterone sandwich method antibody mAb7 or an antigen binding fragment thereof, and a preparation method and application thereof. The aldosterone sandwich method antibody mAb7 or the antigen binding fragment thereof comprises a light chain variable region VL and a heavy chain variable region VH, the light chain variable region VL comprises complementary determining regions LCDR1, LCDR2 and LCDR3, the amino acid sequences of the light chain variable region VL and the heavy chain variable region VH are respectively shown as SEQ ID NO.1-3, the heavy chain variable region VH comprises complementary determining regions HCDR1, HCDR2 and HCDR3, and the amino acid sequences of the heavy chain variable region VH are respectively shown as SEQ ID NO.4-6. When the aldosterone sandwich method antibody mAb7 is used for detecting aldosterone standard antigens, the detection sensitivity is lower than 10 pg / mL, a clinical sample is detected through a magnetochemiluminescence method, the correlation with R clinical comparison is good in the sample range of 0-1000 pg / mL, and the aldosterone sandwich method antibody mAb7 has important significance in the field of diagnosis and treatment of primary hypertension and other aldosterone abnormality related diseases.

This invention relates generally to methods and pharmaceutical formulations useful in treating patients suffering from sleep apnea, including obstructive sleep apnea syndrome (OSAS). Treatment is effected by administering a carbonic anhydrase inhibitor to the patient in combination with an aldosterone antagonist. Formulations containing a therapeutically effective amount of a carbonic anhydrase inhibitor and a therapeutically effective amount of an aldosterone antagonist are provided as well.

This invention belongs to the field of bioassay technology, specifically relating to a cationic COF material and its application in the detection of angiotensin and aldosterone. Specifically, this invention successfully synthesizes a cationic covalent organic framework material with high specific surface area, abundant porous structure, and good thermal / chemical stability. Its surface quaternary ammonium salt cationic functional groups can selectively adsorb negatively charged angiotensin via electrostatic interactions and adsorb aldosterone via π-π conjugation and hydrophobic interactions. It exhibits excellent enrichment capacity and selectivity for four substances: Ang I, Ang II, Ang III, and Aldo, and can be recycled multiple times, effectively reducing the detection cost of large batches of clinical samples. By coupling the prepared SPE material with LC-MS / MS, a method for the simultaneous detection of Ang I, Ang II, Ang III, and Aldo in plasma was established, demonstrating good practical application value.

The invention belongs to the technical field of biological medicine, and relates to application of PARP1 as an MR co-regulatory factor in treatment of hypertension renal injury. The invention discovers that the expression of PARP1 in kidney tissues of a salt-sensitive hypertension renal injury rat model is up-regulated for the first time, and the expression of PARP1 in an aldosterone-induced human renal tubular epithelial cell injury model is also up-regulated; the PARP1 specific inhibitor PJ34 is adopted, so that the renal injury process of human renal tubular epithelial cells induced by aldosterone in vitro can be obviously reversed; in addition, PARP1 protein expression in in-vivo and in-vitro hypertensive renal injury models can be remarkably inhibited and the renal injury process can be effectively relieved by applying an MR antagonist fenerenone; the invention also discloses a functional interaction mechanism between the PARP1 and the MR, and the function can be completely blocked by the fenerenone. Therefore, the PARP1 can be used as a drug, a drug target or a target gene in gene therapy, is applied to prevention, alleviation and treatment of hypertension kidney injury, and can provide a new strategy for prevention and treatment of diseases.

The present invention belongs to the technical field of plant extraction. Disclosed are a medium-chain inulin, a preparation method therefor, and the use thereof. The unique inulin structure and chain length disclosed in the present invention reshape the gut microbiome and metabolome, and in particular, selectively modulate key microorganisms such as Faecalibacterium, Bifidobacterium, Parabacteroides, Clostridium_sensu_stricto_1 and Akkermansia, and metabolites such as nicotinamide, taurocholic acid, aldosterone, corticosterone, 2-(1H-indol-3-yl)acetic acid, 5-hydroxy-L-tryptophan, 5α-DHT and maltose, thereby promoting the amelioration of obesity and the improvement of the overall health of a host. The core microorganisms and metabolites identified by the technical solution represent potential therapeutic targets for preventing or treating obesity and related metabolic symptoms. These findings support the development of inulin-based nutritional strategies to effectively manage body weight by modulating specific microbiota and the metabolome.

The present disclosure provides compounds, compositions, and methods for modulating plasma membrane Cav1.3 calcium channels and treating diseases or disorders (e.g., Parkinson's disease, aldosteronism) with the compounds or compositions thereof. In particular, disclosed herein are modified pyrimidine-2,4,6-triones and modified dihydropyridines that have elevated potency and selectivity for Cav1.3 Ca2+ channels, and compositions and formulations thereof.

The invention is applicable to the technical field of biomedicine, relates to a construction method and application of a diuretic-resistant cell model, and establishes the diuretic-resistant cell model by using angiotensin II and aldosterone to jointly induce mouse renal manifold M-1 cells. The model is verified by detecting gene and protein expression levels of aquaporin 2, epithelial sodium channel alpha subunit and arginine vasopressin receptor 2. The method is simple to construct and good in repeatability, can truly reflect the pathological characteristics of diuretic resistance, can stably simulate the state of water-sodium retention caused by excessive activation of a renin-angiotensin-aldosterone system, can reproduce the core characteristic of insufficient curative effect of the diuretic, verifies the occurrence effect of the diuretic resistance, and has a good application prospect. And a stable and controllable in-vitro model is provided for researching a molecular mechanism of diuretic resistance and screening prevention and treatment drugs.

The invention relates to the technical field of artificial intelligence, in particular to a heart disease cause reasoning system based on a mapping knowledge domain, which comprises a physiological status mapping module, a data processing module, a data processing module and a data processing module, the numerical logic operation module calculates an aldosterone rennin ratio and generates an endocrine abnormal state in combination with a posture corresponding threshold value, the physiological suppression verification module generates a secretion characteristic identifier based on the amplitude of reexamination concentration exceeding a physiological threshold value, and the pathogenic path generation module retrieves lesion nodes and constructs a weighted directed pathogenic edge. According to the method, the physiological indexes are mapped into the map entities, hormone dynamic ratio calculation and self-adaptive threshold screening are executed, negative feedback regulation is simulated in combination with inhibition test data, autonomous secretion characteristics are analyzed, and a causal path is constructed, so that deep source tracing of secondary pathogenic inducements is realized; the problem that complex endocrine lesions cannot be recognized through single linear judgment is effectively solved.

Compositions and methods for treating or preventing a condition related to myocardial infarction and infarct expansion, extension, and / or dilation following a cardiovascular disorder incident (e.g., post-myocardial infarction) using an effective amount of RRx-001, or a pharmaceutically acceptable salt thereof, are described. In some embodiments, an agent (such as a statin, an angiotension-converting-enzyme (ACE) inhibitor, aspirin, oxygen, a nitric oxide donor, a drug-eluting stent, an anticoagulant or antiplatelet therapy, a phosphodiesterase-5 inhibitor, a calcium channel blocker, an angiotensin II receptor blocker (ARB), a beta blocker, an aldosterone antagonist, a loop diuretic, an epigenetic inhibitor, and / or a nitrite) is administered prior to, concurrently with, or subsequent administering the effective amount of RRx-001, or a pharmaceutically acceptable salt thereof. In some embodiments, the effective amount of RRx-001, or a pharmaceutically acceptable salt thereof, is administered as a composition comprising a blood product and / or the agent.

The application belongs to the technical field of biology and particularly relates to a construction method of a Cyp11b2-P2A-CreERT2 gene knock-in mouse model and application thereof. The construction method comprises the following steps: introducing a CRISPR / Cas9 system and a homologous recombination donor vector into a mouse zygote, then transplanting the zygote into a pseudopregnant female mouse, and waiting for the female mouse to become pregnant and give birth to a baby; F0 generation of the recipient mouse is born, the genotype is confirmed, and after the positive F0 generation mouse matures, the mouse is mated with a wild-type background mouse to generate F1 generation, the genotype is confirmed, and the obtained heterozygote is the Cyp11b2-P2A-CreERT2 gene knock-in mouse model. The mouse model constructed by the construction method can realize specific expression of Cre in adrenal glomerular zone, is time and space controllable and has no off-target, the P2A peptide guarantees normal expression of the gene independently, the traditional model defects are avoided, the mouse model is stable, repeatable, and can be used for aldosterone-related mechanism research and drug screening.

The present invention relates to a polyherbal compound based formulation for managing hypertension and related disorders, comprising Dioscin, Withanolide A, Withaferin A, Withanolide D, P-Sitosterol, Diosgenin, Arjunolic Acid, Caffeic Acid, and Kaempferol. The compounds targets multiple mechanistic pathways in hypertension, including the Renin- Angiotensin-Aldosterone System (RAAS), Sympathetic Nervous System, Vascular Resistance, Nitric Oxide, and Stress-Responsive pathways. It offers a comprehensive and synergistic approach for improving vascular health, reducing blood pressure, regulating the levels of HDL and lowering of Cholesterol, LDL and Triglycerides. The compound / s is formulated for enhanced bioavailability and efficacy, and can be used as an adjuvant with antihypertensive agents. The invention also includes methods for extracting, purifying, and standardizing the active ingredients, ensuring consistent quality. The compounds is suitable for managing hypertension, cardiovascular diseases, metabolic disorders, and stress. It can be administered in various dosage forms such as tablets, capsules, syrups, and powders.